Physician profile
Robert C Prentice
NPI 1194789354
$3,153.49
in general payments reported to CMS, 2019-2025
24 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $370 · 2021: $834 · 2022: $264 · 2023: $343 · 2024: $648 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $741.75 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $379.41 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $328.47 | 2019-2021 | |
| Pfizer INC. | $282.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.70 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $189.16 | 2019-2025 | Camzyos |
| Amarin Pharma, INC. | $161.82 | 2019-2022 | |
| Amgen INC. | $149.32 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.26 | 2021-2024 | Lifevest |
| Abbott Laboratories | $101.08 | 2023 | Mitraclip |
| Chiesi USA, INC. | $92.79 | 2019-2021 | |
| Scpharmaceuticals INC. | $91.22 | 2023-2024 | |
| Novo Nordisk INC | $67.72 | 2021-2024 | Wegovy |
| Medtronic, INC. | $33.18 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $32.95 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $26.95 | 2025 | |
| Boston Scientific Corporation | $26.42 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $23.25 | 2023 | Inpefa |
| Edwards Lifesciences Corporation | $18.48 | 2023 | Sapien 3 Ultra Resilia |
| Philips North America LLC | $16.30 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.00 | 2021 | |
| Portola Pharmaceuticals, LLC | $15.75 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.64 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.62 | 2023 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Prentice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.